IART
Integra Lifesciences Holdings Corp
$
15.130
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.1775
Open
15.110
VWAP
14.68
Vol
1.56M
Mkt Cap
1.18B
Low
14.320
Amount
22.89M
EV/EBITDA(TTM)
9.16
Total Shares
78.80M
EV
2.77B
EV/OCF(TTM)
39.01
P/S(TTM)
0.71
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
401.36M
+4.89%
0.504
+23%
456.20M
+3.06%
0.915
-5.64%
414.31M
+8.79%
0.435
+6.09%
Estimates Revision
The market is revising Upward the revenue expectations for Integra LifeSciences Holdings Corporation (IART) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by 16.03%.
Revenue Estimates for FY2025
Revise Upward
+0.14%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-1.12%
In Past 3 Month
Stock Price
Go Up
+16.03%
In Past 3 Month
5 Analyst Rating
15.66% Upside
Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 17.50 USD with a low forecast of 13.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
1 Sell
Hold
15.66% Upside
Current: 15.130
Low
13.00
Averages
17.50
High
25.00
15.66% Upside
Current: 15.130
Low
13.00
Averages
17.50
High
25.00
Citizens JMP
Outperform
downgrade
$35 -> $25
2025-05-09
Reason
Citizens JMP
Price Target
$35 -> $25
2025-05-09
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on Integra LifeSciences to $25 from $35 and keeps an Outperform rating on the shares. Integra's Q1 sales and earnings results were within guidance ranges, but expectations for Q2 were a bit below, the analyst tells investors in a research note. The firm views Monday's 20% selloff on this news as overdone.
Truist Securities
Richard Newitter
Hold
Maintains
$26 → $19
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$26 → $19
2025-04-11
Maintains
Hold
Reason
Truist lowered the firm's price target on Integra LifeSciences to $19 from $26 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
Argus Research
David Toung
Hold
to
Strong Buy
Upgrades
n/a
2025-03-31
Reason
Argus Research
David Toung
Price Target
n/a
2025-03-31
Upgrades
Hold
to
Strong Buy
Reason
Argus upgraded Integra LifeSciences to Buy from Hold.
Citizens Capital Markets
David Turkaly
Buy
Reiterates
$35
2025-02-26
Reason
Citizens Capital Markets
David Turkaly
Price Target
$35
2025-02-26
Reiterates
Buy
Reason
Citigroup
Joanne Wuensch
Strong Sell
Maintains
$16 → $22
2024-11-05
Reason
Citigroup
Joanne Wuensch
Price Target
$16 → $22
2024-11-05
Maintains
Strong Sell
Reason
Citi raised the firm's price target on Integra LifeSciences to $22 from $16 and keeps a Sell rating on the shares. The company reported a somewhat better than expected Q3, the analyst tells investors in a research note. The firm says likely the most important part of the Q3 call was the appointment of Mojdeh Poul as new CEO effective January, "bringing fresh eyes to the organization."
Truist Securities
Richard Newitter
Hold
Maintains
$26 → $21
2024-10-14
Reason
Truist Securities
Richard Newitter
Price Target
$26 → $21
2024-10-14
Maintains
Hold
Reason
Truist lowered the firm's price target on Integra LifeSciences to $21 from $26 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get "a pass" from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that a valuation discount is justified given the accumulating execution errors on the part of the company as well as peers' faster growth prospects.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Integra Lifesciences Holdings Corp (IART.O) is 6.30, compared to its 5-year average forward P/E of 15.07. For a more detailed relative valuation and DCF analysis to assess Integra Lifesciences Holdings Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
15.07
Current PE
6.30
Overvalued PE
20.49
Undervalued PE
9.66
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
13.46
Current EV/EBITDA
8.72
Overvalued EV/EBITDA
16.57
Undervalued EV/EBITDA
10.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
2.40
Current PS
0.69
Overvalued PS
3.46
Undervalued PS
1.33
Financials
Annual
Quarterly
FY2025Q2
YoY :
-0.61%
415.61M
Total Revenue
FY2025Q2
YoY :
-30.22%
33.47M
Operating Profit
FY2025Q2
YoY :
+3803.18%
-484.07M
Net Income after Tax
FY2025Q2
YoY :
+3843.75%
-6.31
EPS - Diluted
FY2025Q2
YoY :
-204.98%
-11.23M
Free Cash Flow
FY2025Q2
YoY :
-8.19%
54.24
Gross Profit Margin - %
FY2025Q2
YoY :
-177.66%
-2.92
FCF Margin - %
FY2025Q2
YoY :
+3821.55%
-116.47
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 449.26% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
141.2K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
203.8K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.0M
Volume
Months
6-9
2
3.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 449.26% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
141.2K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IART News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
06:05:23
Integra LifeSciences backs FY25 adjusted EPS view $2.19-$2.29, consensus $2.24
2025-07-31
06:03:50
Integra LifeSciences sees Q3 adjusted EPS 40c-45c, consensus 58c
2025-07-31
06:02:47
Integra LifeSciences reports Q2 adjusted EPS 45c, consensus 43c
Sign Up For More Events
Sign Up For More Events
News
1.0
08-29NewsfilterIntegra LifeSciences Executives to Speak at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
2.0
07-31CNBCStocks making the biggest moves midday: Generac, Shake Shack, Microsoft, Meta & more
9.5
07-31NASDAQ.COMIntegra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Sign Up For More News
People Also Watch
PPBT
Purple Biotech Ltd
1.420
USD
0.00%
LOB
Live Oak Bancshares Inc
37.540
USD
-0.11%
SID
Companhia Siderurgica Nacional SA
1.390
USD
-0.71%
JAMF
Jamf Holding Corp
9.120
USD
+0.44%
DRH
Diamondrock Hospitality Co
8.490
USD
+0.71%
AGM
Federal Agricultural Mortgage Corp
204.680
USD
-0.97%
UAA
Under Armour Inc
5.060
USD
+0.60%
TXG
10X Genomics Inc
13.340
USD
-0.22%
AGIO
Agios Pharmaceuticals Inc
40.610
USD
+3.46%
CMPR
Cimpress PLC
60.750
USD
-2.74%
FAQ
What is Integra Lifesciences Holdings Corp (IART) stock price today?
The current price of IART is 15.13 USD — it has decreased -0.2 % in the last trading day.
What is Integra Lifesciences Holdings Corp (IART)'s business?
What is the price predicton of IART Stock?
What is Integra Lifesciences Holdings Corp (IART)'s revenue for the last quarter?
What is Integra Lifesciences Holdings Corp (IART)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Integra Lifesciences Holdings Corp (IART)'s fundamentals?
How many employees does Integra Lifesciences Holdings Corp (IART). have?